Table 2.

Model for time to relapse controlling for prednisone at 6 months, months of induction cyclophosphamide, age, race, PR3-ANCA, or use of any remission maintenance medication

ParameterP ValueHazard Ratio95% Confidence Interval
Prednisone at 6 mo, 5 versus 0 mg0.490.690.23–2.02
Prednisone at 6 mo, >5 versus 0 mg0.971.010.57–1.81
Cyclophosphamide induction therapy (mo)0.810.990.92–1.06
Age at diagnosis (yr)0.390.990.98–1.01
Caucasian Race, Caucasian versus non-Caucasian0.910.960.45–2.02
PR3-ANCA versus MPO-ANCA0.021.911.1–3.3
Maintenance immunosuppression (mo)a0.401.010.99–1.02
  • PR3-ANCA, proteinase 3 antineutrophil cytoplasmic antibody; MPO-ANCA, myeloperoxidase antineutrophil cytoplasmic antibody.

  • a Immunosuppression other than glucocorticoids or cyclophosphamide.